Skip to main content
. 2019 Oct 4;25(6):326–335. doi: 10.5761/atcs.oa.19-00093

Table 1. Patients’ baseline characteristics.

Variable Overall
LVEF <50%
(n = 557)
Group 1
LVEF 40%–49%
(n = 294)
Group 2
LVEF 30%–39%
(n = 145)
Group 3
LVEF <30%
(n = 118)
P

Mean age, years 62.8 ± 11.7 63.5 ± 12.2 64.1 ± 10.3 59.5 ± 11.6 0.002
Male gender, n (%) 320 (57.4) 167 (56.8) 77 (53.1) 76 (64.4) 0.173
BMI, kg/m2 26.8 ± 5.5 25.7 ± 5.0 26.8 ± 5.9 25.8 ± 6.2 0.397
Diabetes mellitus, n (%) 110 (19.7) 52 (17.6) 35 (24.1) 23 (19.4) 0.279
Hypertension, n (%) 357 (64) 206 (70.0) 101 (69.7) 50 (42.3) <0.001
COPD, n (%) 29 (5.2) 15 (5.1) 5 (3.4) 9 (7.6) 0.314
PAD, n (%) 29 (5.2) 18 (6.1) 6 (4.1) 5 (4.2) 0.589
PHT >60 mmHg, n (%) 108 (19.4) 58 (19.7) 30 (20.7) 20 (16.9) 0.600
CAD
 1-Vessel, n (%) 56 (10.0) 28 (9.5) 20 (13.8) 8 (6.8)
 2-Vessels, n (%) 22 (3.9) 11 (3.7) 8 (5.5) 3 (2.5) 0.335
 3-Vessels, n (%) 14 (2.5) 7 (2.4) 5 (3.4) 2 (1.7)
AFIB, n (%) 215 (38.6) 124 (42.2) 77 (53.1) 37 (31.3) 0.274
NYHA functional lass
 I/II, n (%) 250 (44.9) 174 (59.2) 56 (38.6) 20 (16.9)
 III, n (%) 232 (41.6) 93 (31.6) 68 (46.9) 71 (60.2) <0.001
 IV, n (%) 75 (13.5) 27 (9.2) 21 (14.5) 27 (22.9)
MR grade
 Moderate-to-severe, n (%) 23 (4.1) 13 (4.4) 6 (4.1) 4 (3.3) 0.893
 Severe, n (%) 534 (95.9) 281 (95.6) 138 (95.9) 114 (96.6)
LVEF, % 36.8 ± 9.4 44.3 ± 2.8 33.7 ± 2.8 22.2 ± 5.1 <0.001
Cardiomyopathy
 Non-ischemic dilated, n (%) 487 (87.4) 258 (87.7) 122 (84.1) 108 (91.5) 0.186
 Ischemic, n (%) 70 (12.6) 36 (12.3) 23 (15.9) 10 (8.5)
Logistic EuroSCORE, % 7.2 ± 5.7 6.3 ± 4.8 7.4 ± 6.0 9.3 ± 6.7 <0.001

AFIB: atrial fibrillation; BMI: body mass index; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; LVEF: left ventricular ejection fraction; MR: mitral regurgitation; NYHA: New York Heart Association; PAD: peripheral arterial disease